TAT 2012 was the tenth meeting in the series named in full "International Congress on Targeted Anticancer Therapies". Like all TAT meetings held since 2005, TAT 2012 was another official ESMO Partnership Meeting. TAT 2012 was offered by the Amsterdam-based NDDO Education Foundation, and was co-sponsored by the U.S. National Cancer Institute - Centre for Cancer Research.
TAT meetings are characterized by their focus on targeted cancer therapeutics, in particular the most promising ones in the late preclinical and early clinical development stages. TAT 2012 offered excellent opportunities for the presentation and discussion of ongoing and completed phase 1 studies in a highly interactive setting. Apart from being of importance to everyone involved in anticancer drug development on a daily basis, the TAT 2012 programme was also be of educational value to oncologists wishing to stay abreast of emerging new treatment options.
Distinguishing features of TAT 2012:
- Highly focused on early phase development of promising targeted agents for cancer therapy
- Medium-sized event, creating excellent possibilities for personal interactions with colleagues
- Participants from academia and industry
- No parallel sessions, avoiding the need to make difficult choices
- Attention to methodological and regulatory issues in new drug development
- Ample opportunity to present your own work in front of an international expert audience
Visit TAT 2012 website for more information